Astellas Pharma, Inc.
Most Recent
How Is Merck’s Hospital Acute Care Segment Positioned?
Merck & Company’s (MRK) Bridion generated revenue of $204 million in Q1 2018 compared to $148 million in Q1 2017.
Updates on AbbVie’s AndroGel, Lupron, and Kaletra
In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter.
Understanding FibroGen’s Research Pipeline
Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200.
A Look at Novartis’s Immunology and Dermatology Segment’s Performance
In 4Q17, Novartis’s Immunology and Dermatology segment generated revenues of $1.2 billion, ~30% growth on a year-over-year (or YoY) basis and ~9% growth quarter-over-quarter.
How Did Merck’s Invanz and Cancidas Perform in 2017?
In 4Q17, Merck’s (MRK) Invanz generated revenues of $157 million, which represents a ~3% rise on a YoY (year-over-year) basis.
Behind Valeant’s Branded Drugs: Other 3Q17 Performances
In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.
How Johnson & Johnson’s Zytiga Performed in 3Q17
In 3Q17, Johnson & Johnson’s (JNJ) Zytiga generated revenues of $669 million, which reflected ~15% growth on a year-over-year (or YoY) basis and 20% growth on a quarter-over-quarter basis.
An Overview of Trulance: Synergy Pharmaceuticals’ First Commercialized Drug
Since its launch, Synergy’s (SGYP) Trulance sales have been steadily rising. In 3Q17, more than 25,000 prescriptions were filled for the drug.
How Novartis’s Immunology and Dermatology Portfolio Looks after 3Q17
In 3Q17, Novartis’s (NVS) Neoral generated revenues of ~$126 million, which represents a ~3% YoY (year-over-year) fall and a 2% QoQ fall.
Why Lupron Could Continue to Generate Steady Revenue
In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.
Company & Industry Overviews Depressed Consumer Spending Hurt the Fidelity Advisor Overseas Fund
The Fidelity Advisor Overseas Fund – Class A (FAOAX) has emerged as a below-average performer in YTD 2016 among the 12 funds chosen for this review.
What’s the Sector Composition of the Fidelity Advisor Overseas Fund?
The Fidelity Advisor Overseas Fund invests at least 80% of its net assets in common stocks of non-US issuers.
Company & Industry Overviews Why 2016 Has Been Forgettable for the BlackRock Pacific Fund
Financials have contributed the lion’s share of the BlackRock Pacific Fund – Investor A Shares’ (MDPCX) poor showing in 2016 YTD.
How Is the Invesco Pacific Growth Fund Allocating Its Portfolio?
TGRAX is quite balanced as far as allocation in its top three sectors is concerned.
The Fidelity Advisor Overseas Fund’s Portfolio Moves in YTD 2016
The Fidelity Advisor Overseas Fund’s (FAOAX) top sectoral bet is the consumer discretionary sector, which forms one-fourth of the fund’s total assets.
Healthcare Stocks Save the Day for CNJFX
Financials were the biggest negative contributors to CNJFX’s total returns in the first four months of 2016.
The Story behind Medivation’s Rising Collaboration Revenue
Medivation (MDVN) earned collaboration revenue from Xtandi’s US and non-US sales along with upfront and milestone payments.
What’s the Drug Approval Process in Japan?
The drug approval process in Japan includes a sequence of non-clinical studies, clinical studies followed by approval review, and post-marketing surveillance.
How Are Drugs Priced in Japan?
The NHI revises drug prices every two years. During fiscal 2016, a 6.8% reduction in drug prices is expected.
What You Should Know about the Fidelity Advisor Overseas Fund
The Fidelity Advisor Overseas Fund – Class A (FAOAX) was incepted in September 1996 and has an expense ratio of 1.4%.
PRITX’s Recent Performance: What Does This Mean for Investors?
The T. Rowe Price International Stock Fund (PRITX) has been in existence since May 1980.
Get Your Essentials on the Invesco Pacific Growth Fund (TGRAX)
The Invesco Pacific Growth Fund, under normal circumstances, will invest “at least 80% of its net assets in securities of issuers in the Pacific region.”
Meet the Columbia Pacific/Asia Fund (CASAX)
The Columbia Pacific/Asia Fund (CASAX) aims to invest 80% of its net assets in equity securities of companies “located in Asia and the Pacific Basin.
A Portfolio Scan of the T. Rowe Price Japan Fund in 2015
The T. Rowe Price Japan Fund (PRJPX) is well diversified with 78 holdings as of December 2015. It was managing assets worth $330.08 million at the end of December.
A Portfolio Scan of the Fidelity Japan Fund in 2015
The Fidelity Japan Fund’s (FJPNX) assets were spread across 86 securities as of December 2015 and it was managing $545.18 million in assets.
Market Response to Xalkori’s Label Update
Observing the changes in Pfizer’s stock price after Xalkori’s label update by the European Commission shows that the stock price rose by ~2.8%.
Insight on Profile 1014: Phase III Study for Xalkori
Profile 1014 is the Phase III study for Xalkori, an ALK inhibitor. As per Pfizer’s press release, study was a randomized, and involved 343 patients.
Pfizer’s Xalkori Approved by the European Commission
Pfizer’s oncology drug Xalkori, also termed Crizotinib, was approved for label expansion and label update by the European Commission on November 25.
Assessing the Fidelity Japan Fund (FJPNX): Historical Overview
The Fidelity Japan Fund invests at least 80% of its assets in securities of Japanese issuers and other investments that are tied economically to Japan.
How the Voya Japan TOPIX Index Portfolio Class A Fared in September 2015
The Voya Japan TOPIX Index Portfolio fell by 6.7% in September 2015 from the previous month.
The Voya Japan TOPIX Index Portfolio Class A (IJIAX): Historical Overview
The Voya Japan TOPIX Index Portfolio Class A is an index fund, not an actively managed mutual fund, so it necessarily tracks its benchmark index.
Macroeconomic Analysis Stock Selection Saves the Nuveen Tradewinds Japan Fund – A
The Nuveen Tradewinds Japan Fund – A (NTJAX) fell 4.4% in August from a month ago. In the three-month period ended August 31, it fell 2.1%, the third least faller.